MGC Pharma completes construction of COVID-19 medicine production facility in Malta

MGC Pharmaceuticals, a European-based bio-pharma company, announced the completion of the construction and implementation phase of the CimetrA™ production facility in Malta.

Preclinical and clinical results have shown that CimetrA™ is effective in the prevention of severe inflammation caused by the infection of the different COVID-19 variants. Such inflammation is believed to be the main reason for mortality in severe COVID-19 patients.

“The completion of the construction of the CimetrA™ facility in Malta, the company’s second EU-based production facility, continues to strengthen our strategic position in pharmaceuticals development and manufacturing,” MGC Pharma Co-Founder and Managing Director Roby Zomer said.

“[This] provides the company with flexible production capacity, which includes production of CimetrA™, MGC Pharma’s proprietary treatment for the symptoms of COVID-19,” Mr Zomer concluded.

MGC Pharma received €3.1 million cash grant from the Maltese Government via Malta Enterprise in order to fund the majority of the costs of construction and equipment fitout of the facility.

The facility will have the capacity to produce over 20,000 units of CimetrA™ in liquid dose form per day, which is double that originally planned.

“Malta Enterprise is proud to support MGC Pharmaceuticals in developing and producing CimetrA™ through the COVID-19 Investment Aid fund, which was set up to assist companies develop products in the fight against the pandemic,” Malta Enterprise CEO Kurt Farrugia said.

“This project is a great example of how both MGC and ME seized an opportunity during critical circumstances and we are thrilled that CimetrA™, a potential solution to mitigate the effects of the Coronavirus, will carry the ‘made in Malta’ brand,” Mr Farrugia concluded.